Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study
- PMID: 17919486
- PMCID: PMC2175077
- DOI: 10.1053/j.gastro.2007.08.001
Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study
Abstract
Background & aims: Although inflammation is presumed to contribute to colonic neoplasia in ulcerative colitis (UC), few studies have directly examined this relationship. Our aim was to determine whether severity of microscopic inflammation over time is an independent risk factor for neoplastic progression in UC.
Methods: A cohort of patients with UC undergoing regular endoscopic surveillance for dysplasia was studied. Degree of inflammation at each biopsy site had been graded as part of routine clinical care using a highly reproducible histologic activity index. Progression to neoplasia was analyzed in proportional hazards models with inflammation summarized in 3 different ways and each included as a time-changing covariate: (1) mean inflammatory score (IS-mean), (2) binary inflammatory score (IS-bin), and (3) maximum inflammatory score (IS-max). Potential confounders were analyzed in univariate testing and, when significant, in a multivariable model.
Results: Of 418 patients who met inclusion criteria, 15 progressed to advanced neoplasia (high-grade dysplasia or colorectal cancer), and 65 progressed to any neoplasia (low-grade dysplasia, high-grade dysplasia, or colorectal cancer). Univariate analysis demonstrated significant relationships between histologic inflammation over time and progression to advanced neoplasia (hazard ration (HR), 3.0; 95% CI: 1.4-6.3 for IS-mean; HR, 3.4; 95% CI: 1.1-10.4 for IS-bin; and HR, 2.2; 95% CI: 1.2-4.2 for IS-max). This association was maintained in multivariable proportional hazards analysis.
Conclusions: The severity of microscopic inflammation over time is an independent risk factor for developing advanced colorectal neoplasia among patients with long-standing UC.
Figures
Comment in
-
Ulcerative colitis surveillance: activity does matter.Inflamm Bowel Dis. 2008 Oct;14(10):1453-4. doi: 10.1002/ibd.20468. Inflamm Bowel Dis. 2008. PMID: 18393374 No abstract available.
Similar articles
-
Increased Active Inflammation in the Colon is Not a Reliable Predictor of an Elevated Risk of Dysplasia in Patients With Primary Sclerosing Cholangitis and Ulcerative Colitis.Am J Surg Pathol. 2024 Sep 1;48(9):1154-1163. doi: 10.1097/PAS.0000000000002255. Epub 2024 May 29. Am J Surg Pathol. 2024. PMID: 38809303
-
Validated Indices for Histopathologic Activity Predict Development of Colorectal Neoplasia in Ulcerative Colitis.J Crohns Colitis. 2021 Sep 25;15(9):1481-1490. doi: 10.1093/ecco-jcc/jjab042. J Crohns Colitis. 2021. PMID: 33687061
-
Progression of low-grade dysplasia in ulcerative colitis: effect of colonic location.Gastrointest Endosc. 2011 Nov;74(5):1087-93. doi: 10.1016/j.gie.2011.06.028. Epub 2011 Sep 10. Gastrointest Endosc. 2011. PMID: 21907984
-
Impact of mucosal inflammation on risk of colorectal neoplasia in patients with ulcerative colitis: a systematic review and meta-analysis.Gastrointest Endosc. 2017 Dec;86(6):1006-1011.e8. doi: 10.1016/j.gie.2017.07.028. Epub 2017 Jul 24. Gastrointest Endosc. 2017. PMID: 28750838 Review.
-
Dysplasia in ulcerative colitis--clinical consequences?Langenbecks Arch Surg. 2004 Oct;389(5):354-60. doi: 10.1007/s00423-003-0455-6. Epub 2004 Mar 13. Langenbecks Arch Surg. 2004. PMID: 15605166 Review.
Cited by
-
A breakthrough in probiotics: Clostridium butyricum regulates gut homeostasis and anti-inflammatory response in inflammatory bowel disease.J Gastroenterol. 2015 Sep;50(9):928-39. doi: 10.1007/s00535-015-1084-x. Epub 2015 May 5. J Gastroenterol. 2015. PMID: 25940150 Review.
-
Does aspirin or non-aspirin non-steroidal anti-inflammatory drug use prevent colorectal cancer in inflammatory bowel disease?World J Gastroenterol. 2016 Apr 7;22(13):3679-86. doi: 10.3748/wjg.v22.i13.3679. World J Gastroenterol. 2016. PMID: 27053860 Free PMC article. Review.
-
Validation of the 'Inflammatory Bowel Disease-Distribution, Chronicity, Activity [IBD-DCA] Score' for Ulcerative Colitis and Crohn´s Disease.J Crohns Colitis. 2021 Oct 7;15(10):1621-1630. doi: 10.1093/ecco-jcc/jjab055. J Crohns Colitis. 2021. PMID: 33773497 Free PMC article.
-
Ulcerative Colitis: What is the Optimal Treatment Goal and How Do We Achieve It?Curr Treat Options Gastroenterol. 2015 Mar;13(1):130-42. doi: 10.1007/s11938-014-0044-5. Curr Treat Options Gastroenterol. 2015. PMID: 25619458
-
Evaluation of Disease Activity in Inflammatory Bowel Disease: Diagnostic Tools in the Assessment of Histological Healing.Biomedicines. 2023 Nov 18;11(11):3090. doi: 10.3390/biomedicines11113090. Biomedicines. 2023. PMID: 38002090 Free PMC article. Review.
References
-
- Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology. 2004;126:1634–48. - PubMed
-
- Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323:1228–33. - PubMed
-
- Connell WR, Lennard-Jones JE, Williams CB, Talbot IC, Price AB, Wilkinson KH. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis [see comments] Gastroenterology. 1994;107:934–44. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous